NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis<
29 Mar 2022

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights<
23 Mar 2022

Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights

On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)<
21 Mar 2022

Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)

AU-011 was previously granted Orphan Drug Designation for the treatment of uveal melanoma by the U.S. Food and Drug Administration.
CorWave to set up its manufacturing facility and expand to a new site next to Paris<
17 Mar 2022

CorWave to set up its manufacturing facility and expand to a new site next to Paris

The industrial start-up is preparing to move to larger premises capable of hosting its R&D center and the manufacturing facility needed to enter the clinical and commercial phases.
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22<
15 Mar 2022

Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22

The program will include an overview of choroidal melanoma (CM), AU-011’s novel mechanism of action.
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022<
10 Mar 2022

LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022

The recording will be available following the conference under the "Events" tab on the investor relations section of the LAVA Therapeutics
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare<
08 Mar 2022

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives
Lava Therapeutics presents initial LAVA-051 clinical data at the ESMO Targeted Anticancer Therapies Congress 2022<
08 Mar 2022

Lava Therapeutics presents initial LAVA-051 clinical data at the ESMO Targeted Anticancer Therapies Congress 2022

LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome
Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting<
08 Mar 2022

Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

The results demonstrate the potential wide applicability of AU-011 in targeting a number of solid tumor types
Am-Pharma announces two presentations at the 27th international conference on advances in critical care nephrology<
07 Mar 2022

Am-Pharma announces two presentations at the 27th international conference on advances in critical care nephrology

New data underscoring the correlation between acute kidney injury severity and patient outcomes following cardiac surgery.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.